Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.62 |
| ▸ | SLC6A7 | Q99884 | 5/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968427 | 1.00 | TIPARP (0.62) | TIPARPSLC6A7MRGPRX4PARP1ALDH1A1 | |
| SCHEMBL24968300 | 0.80 | TIPARP (0.75) | TIPARPSLC6A7PARP1KDM4EMGLL | |
| SCHEMBL30165098 | 0.80 | TIPARP (0.75) | TIPARPSLC6A7PARP1KDM4EMGLL | |
| SCHEMBL30851256 | 0.80 | MRGPRX4 (0.59) | MRGPRX4 | |
| SCHEMBL24968426 | 0.80 | MRGPRX4 (0.59) | MRGPRX4 | |
| SCHEMBL25270477 | 0.77 | TIPARP (1.00) | TIPARPPARP1 | |
| SCHEMBL24968420 | 0.76 | MRGPRX4 (0.53) | MRGPRX4LMNA | |
| SCHEMBL30390234 | 0.76 | TIPARP (0.60) | TIPARPSLC6A7ALDH1A1LMNAKDM4E | |
| SCHEMBL25272191 | 0.76 | TIPARP (0.60) | TIPARPSLC6A7ALDH1A1LMNAKDM4E | |
| SCHEMBL24968185 | 0.73 | TIPARP (0.44) | TIPARPCHRM2CHRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | TIPARP 142/4885SLC6A7 439/4885MRGPRX4 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.